A large population-level study from the Princess Margaret Cancer Centre in Toronto indicated that "antibiotic exposure and specifically fluoroquinolones before treatment with immune checkpoint inhibitor were associated with worse overall survival, with fluoroquinolone exposure conferring up to a 65% increased risk of mortality among older adults with cancer." Of the 2,737 cancer patients who were administered immune checkpoint inhibitors, 59% received antibiotics 1 year before ICU treatment, while 19% received antibiotics 60 days before ICI. The authors of the study further state that more data is required to further explore the association between antibiotic exposure, ICI treatment and survival outcomes among cancer patients in diverse settings.
To read more about this study, click here.
Sources mentioned:
- Eng L, Sutradhar R, Niu Y, et al. Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. JCO; Published online 24 February 2023. DOI: 10.1200/JCO.22.00074
- Pinato DJ, Cortellini A. Antibiotic Therapy: The Cornerstone of Iatrogenic Resistance to Immune Checkpoint Inhibitors. JCO; Published online 24 February 2023. DOI: 10.1200/JCO.23.00049
No comments:
Post a Comment